Steven Prestrelski - 22 Feb 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
22 Feb 2022
Net transactions value
-$19,411
Form type
4
Filing time
24 Feb 2022, 15:28:23 UTC
Previous filing
05 Jan 2022
Next filing
01 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $7,747 +11,228 +2% $0.6900 581,008 22 Feb 2022 Direct
transaction XERS Common Stock Sale $27,158 -11,228 -1.9% $2.42 569,780 22 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -11,228 -100% $0.000000* 0 22 Feb 2022 Common Stock 11,228 $0.6900 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 $2.4188 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 These options are fully vested as of the date hereof.